Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

NCT05025735 is registered in ClinicalTrials.gov with Saint Luke's Health System as lead sponsor.

NCT NCT05025735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05025735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
Lead sponsor
Saint Luke's Health System
Phase
Phase 2
Overall status
Unknown status
Start date
August 25, 2021
Completion date
July 31, 2023
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative breast cancer, metastatic breast cancer